Clinical review report Levodopa/Carbidopa (Duodopa) (Abbvie Corporation) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Parkinson's disease--Treatment.

Parkinson's disease.

Physical Description:

1 online resource (1 PDF file (128 pages)) : illustrations

Other Title:

Clinical review report Levodopa/Carbidopa

Place of Publication:

Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

The current Common Drug Review (CDR) review was undertaken in response to a request from the drug plans that participate in the CDR review process that the use of levodopa/carbidopa intestinal gel (LCIG) in Parkinson disease (PD) be re-reviewed in light of the availability of new evidence. Therefore, for the current review, new clinical evidence that has become available since the CDR review in 2009 was considered for inclusion in a systematic review to assess the efficacy and harms of LCIG for the treatment of patients with advanced levodopa-responsive PD who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-/dyskinesia despite optimized treatment with available combinations of PD medicinal products, and for whom the benefits of this treatment may outweigh the risks associated with the insertion and long-term use of the percutaneous endoscopic gastrostomy-jejunostomy tube required for administration.

Notes:

Description based on publisher supplied metadata and other sources.